AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 360846 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine hydrochloride (0.5%, 1.0%, 2.0%)
Number of subjects: 36
Study 31337378 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood adversity (≥2 types of events)
Number of subjects: 115
Study 28272337 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic beverage (IB)
Number of subjects: 49
Study 25662861 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogenosulfate (CHS)
Number of subjects: 101
Study 25662861 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel besylate (CB)
Number of subjects: 101
Study 24396214 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation training
Number of subjects: 30
Study 21398419 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 30
Study 21398419 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 18441772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone gel 5% (n=578)
Number of subjects: 1306
Study 18441772 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (n=547)
Number of subjects: 1306
Study 16959675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training 5 days a week for 6 weeks
Number of subjects: 39
Study 16959675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 39
Study 14514389 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg bid for 14 days)
Number of subjects: 68
Study 14514389 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment influencing prolactin or other sexual hormones)
Number of subjects: 68
Study 10611136 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxsalen (50 mg oral)
Number of subjects: 11
Study 10611136 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 11
Study 9088818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 0.5, 1, 2, and 4 micrograms kg‐1 min‐1 for 40 min each
Number of subjects: 20
Study 9088818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9088818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 4 micrograms kg‐1 min‐1
Number of subjects: 20
Study 9088818 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine and Placebo
Number of subjects: 20
Study 7978422 — intervention group
Group type: EXPERIMENTAL
Intervention: GOD‐F method
Number of subjects: 48
Study 7978422 — intervention group
Group type: COMPARATOR
Intervention: Hexokinase method
Number of subjects: 48
Study 2524549 — intervention group
Group type: EXPERIMENTAL
Intervention: MSD recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Number of subjects: 201
Study 2524549 — intervention group
Group type: EXPERIMENTAL
Intervention: SKF recombinant DNA hepatitis B vaccine (2 micrograms doses, 3 doses I.M. at monthly intervals)
Number of subjects: 201
Study 2524549 — intervention group
Group type: COMPARATOR
Intervention: MSD plasma-derived vaccine (2 micrograms doses, 3 doses I.M. at 0, 1, 2 months)
Number of subjects: 201
Study 1201630 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly dose-fractionation (12 fractions in 28 days)
Number of subjects: 411
Study 1201630 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly dose-fractionation (6 fractions in 18 days)
Number of subjects: 411
Study 31160251 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: ipilimumab 3 mg/kg plus nivolumab 1 mg/kg, two cycles every 3 weeks
Number of subjects: 89
Study 31160251 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: ipilimumab 1 mg/kg plus nivolumab 3 mg/kg, two cycles every 3 weeks
Number of subjects: 89
Study 31160251 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: ipilimumab 3 mg/kg for two cycles every 3 weeks followed by nivolumab 3 mg/kg for two cycles every 2 weeks
Number of subjects: 89
Study 29381993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg in 98 mL saline for 20 minutes after induction)
Number of subjects: 100
Study 29381993 — intervention group
Group type: COMPARATOR
Intervention: Control (100 mL saline)
Number of subjects: 100
Study 26474380 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone consultation between pain specialist and primary care physician
Number of subjects: 80
Study 26474380 — intervention group
Group type: COMPARATOR
Intervention: Usual care by primary care physician
Number of subjects: 80
Study 23874094 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 7 days
Number of subjects: 0
Study 23874094 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime 250 mg twice daily for mild-moderate exacerbation or 500 mg twice daily for severe exacerbation for 7 days
Number of subjects: 0
Study 23874094 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 0
Study 23874094 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 0
Study 21208909 — intervention group
Group type: EXPERIMENTAL
Intervention: F4 protein (10, 30, or 90 μg/dose) adjuvanted with AS01
Number of subjects: 180
Study 21208909 — intervention group
Group type: COMPARATOR
Intervention: F4 protein (10, 30, or 90 μg/dose) reconstituted with water for injection
Number of subjects: 180
Study 19805690 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric measurement of minimal residual disease (MRD) at day 15 of induction therapy
Number of subjects: 830
Study 19805690 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometric measurement of MRD
Number of subjects: 830
Study 19805690 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR MRD
Number of subjects: 830
Study 17426059 — intervention group
Group type: EXPERIMENTAL
Intervention: GVD regimen (gemcitabine 1000 mg/m², vinorelbine 20 mg/m², pegylated liposomal doxorubicin 15 mg/m² for transplant-naive patients; gemcitabine 800 mg/m², vinorelbine 15 mg/m², pegylated liposomal doxorubicin 10 mg/m² for post-transplant patients)
Number of subjects: 91
Study 17426059 — intervention group
Group type: EXPERIMENTAL
Intervention: GVD regimen followed by autologous transplant in transplant-naive patients
Number of subjects: 91
Study 17426059 — intervention group
Group type: EXPERIMENTAL
Intervention: GVD regimen in patients with prior transplant failure
Number of subjects: 91
Study 15525924 — intervention group
Group type: EXPERIMENTAL
Intervention: IA morphine with bupivacaine injected 10 minutes before tourniquet release
Number of subjects: 40
Study 15525924 — intervention group
Group type: COMPARATOR
Intervention: IA morphine with bupivacaine injected after tourniquet release
Number of subjects: 40
Study 11494074 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg vardenafil
Number of subjects: 601
Study 11494074 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 601
Study 11494074 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 601
Study 11494074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study 8922361 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 0
Study 8922361 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (RHI)
Number of subjects: 0
Study 1359998 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol 400 micrograms
Number of subjects: 12
Study 1359998 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 500 micrograms
Number of subjects: 12
Study 1359998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4011338 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (30 mg/kg/day)
Number of subjects: 22
Study 4011338 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 22
Study 30556372 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 36
Study 30556372 — intervention group
Group type: COMPARATOR
Intervention: NaF/triclosan dentifrice
Number of subjects: 36
Study 30289905 — intervention group
Group type: EXPERIMENTAL
Intervention: Four coaching sessions after communication skills training
Number of subjects: 72
Study 30289905 — intervention group
Group type: COMPARATOR
Intervention: Single coaching session (control group)
Number of subjects: 72
Study 26655431 — intervention group
Group type: COMPARATOR
Intervention: Physical activity and nutrition intervention delivered through 12 home visits and up to 12 phone calls over 12 months.
Number of subjects: 151
Study 26655431 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and nutrition intervention
Number of subjects: 151
Study 24802283 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap + connective tissue graft (CAF + CTG) with labial submucosal tissue (LST) removal
Number of subjects: 50
Study 24802283 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap + connective tissue graft (CAF + CTG) without LST removal
Number of subjects: 50
Study 24802283 — intervention group
Group type: COMPARATOR
Intervention: Post-operative morbidity evaluation
Number of subjects: 50
Study 22504214 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable Pressure Right acupressure device
Number of subjects: 100
Study 22504214 — intervention group
Group type: COMPARATOR
Intervention: Sham acustimulation device
Number of subjects: 100
Study 19459989 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous HAART
Number of subjects: 69
Study 19459989 — intervention group
Group type: COMPARATOR
Intervention: Intermittent HAART
Number of subjects: 69
Study 17201879 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole (40 mg p.o. twice daily for 3 days)
Number of subjects: 70
Study 17201879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17201879 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 70
Study 15007536 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 30
Study 15007536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12355944 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine or its combination therapies
Number of subjects: 0
Study 12355944 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 0
Study 9718247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (titrated to 50-150 ng/ml)
Number of subjects: 78
Study 9718247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 9718247 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 78
Study 7817271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxyradiotherapy (acute hypoxia)
Number of subjects: 165
Study 7817271 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 165
Study 2113874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil suspension
Number of subjects: 660
Study 2113874 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin syrup
Number of subjects: 660
Study 460026 — intervention group
Group type: EXPERIMENTAL
Intervention: Etozolin (800 mg p.o.)
Number of subjects: 115
Study 460026 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (80 mg p.o.)
Number of subjects: 115
Study 460026 — intervention group
Group type: EXPERIMENTAL
Intervention: Etozolin (800 mg p.o.) and Furosemide (80 mg p.o.)
Number of subjects: 115
Study 30995635 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening procedure and randomized SVD approximation
Number of subjects: 0
Study 30995635 — intervention group
Group type: COMPARATOR
Intervention: Standard Tikhonov regularization with nonnegativity constraint
Number of subjects: 0
Study 27744012 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT, 2×/wk)
Number of subjects: 38
Study 27744012 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump Training (JUMP, 3×/wk)
Number of subjects: 38
Study 25510307 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Tolerance (DT) intervention
Number of subjects: 49
Study 25510307 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE) control
Number of subjects: 49
Study 22917075 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched cheese (90 g/d for 3 weeks)
Number of subjects: 42
Study 22917075 — intervention group
Group type: COMPARATOR
Intervention: Control cheese (90 g/d for 3 weeks)
Number of subjects: 42
Study 20802006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 80 mg/m(2) on days 1 and 29, Irinotecan 60 mg/m(2) on days 1, 8, 15, 29, 36, and 43, and 30 mg/m(2) on days 57, 64, 71, 78, 85 and 92, followed by thoracic radiotherapy starting on day 57 at 2 Gy/day (total 60 Gy)
Number of subjects: 68
Study 20802006 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Irinotecan regimen
Number of subjects: 68
Study 19027265 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cruciate-retaining design
Number of subjects: 200
Study 19027265 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized design
Number of subjects: 200
Study 19027265 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable joint line elevation
Number of subjects: 200
Study 17049894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tulo+Tio (tiotropium added to tulobuterol)
Number of subjects: 60
Study 17049894 — intervention group
Group type: COMPARATOR
Intervention: Tulo (tulobuterol alone)
Number of subjects: 60
Study 14724301 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent
Number of subjects: 1314
Study 14724301 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent
Number of subjects: 1314
Study 11318046 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory metronome
Number of subjects: 0
Study 11318046 — intervention group
Group type: COMPARATOR
Intervention: Visual metronome
Number of subjects: 0
Study 9394979 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied PAF antagonist (RO‐24‐0238)
Number of subjects: 36
Study 9394979 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 36
Study 8186880 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform defibrillation
Number of subjects: 14
Study 8186880 — intervention group
Group type: COMPARATOR
Intervention: Monophasic waveform defibrillation
Number of subjects: 14
Study 2834148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic duct occlusion (PDO) during Whipple's operation
Number of subjects: 0
Study 2834148 — intervention group
Group type: COMPARATOR
Intervention: Whipple's operation without PDO
Number of subjects: 0
Study 29422189 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Skills for Students (MSS)
Number of subjects: 616
Study 29422189 — intervention group
Group type: COMPARATOR
Intervention: Support as usual
Number of subjects: 616
Study 27762662 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1.5‐3.0 mg · kg‐1 day‐1; titrated)
Number of subjects: 18
Study 27762662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27762662 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (postcaf: 358.0 ± 89.8 kJ)
Number of subjects: 18
Study 27762662 — intervention group
Group type: COMPARATOR
Intervention: Placebo (postcaf: 351.8 ± 49.4 kJ)
Number of subjects: 18
Study 27762662 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and Placebo
Number of subjects: 18
Study 26142555 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 110
Study 26142555 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 110
Study 22556317 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous (S) mode
Number of subjects: 10
Study 22556317 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous/timed (S/T) modes (low BURR and high BURR)
Number of subjects: 10
Study 22556317 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BURR (S/T mode)
Number of subjects: 10
Study 22556317 — intervention group
Group type: EXPERIMENTAL
Intervention: High BURR (S/T mode)
Number of subjects: 10
Study 20805430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 3237
Study 20805430 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 3237
Study 18279051 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc lozenges (13.3 mg of zinc as zinc acetate)
Number of subjects: 50
Study 18279051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15689918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose testosterone (T) + letrozole (Lz; 2.5 mg/d)
Number of subjects: 23
Study 15689918 — intervention group
Group type: COMPARATOR
Intervention: Low-dose testosterone (T) + placebo (P)
Number of subjects: 23
Study 14620222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone conversation during the task
Number of subjects: 45
Study 14620222 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking to someone in the same room
Number of subjects: 45
Study 14620222 — intervention group
Group type: COMPARATOR
Intervention: No distractions (Control group)
Number of subjects: 45
Study 10501791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 400 mg daily
Number of subjects: 610
Study 10501791 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg daily
Number of subjects: 610
Study 10501791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 8548515 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐item Philadelphia Geriatric Center Affect Rating Scale
Number of subjects: 296
Study 1985428 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary control of blood phenylalanine below 900 mumol/L maintained beyond age 10 years
Number of subjects: 95
Study 1985428 — intervention group
Group type: COMPARATOR
Intervention: Dietary control not maintained (blood phenylalanine persistently above 900 mumol/L)
Number of subjects: 95
Study 6320622 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 13
Study 6320622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study 6320622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 13
Study 6320622 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 13
Study 31780139 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block with sugammadex reversal
Number of subjects: 100
Study 31780139 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block with neostigmine reversal
Number of subjects: 100
Study 31780139 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative shoulder pain
Number of subjects: 100
Study 31166471 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydraulic pressure delivery system (HPDS) with high-viscosity cement
Number of subjects: 0
Study 31166471 — intervention group
Group type: COMPARATOR
Intervention: Balloon tamp system (BTS) with high-viscosity cement
Number of subjects: 0
Study 28538314 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular dentistry‐designed mouthguard (NMDD)
Number of subjects: 42
Study 28538314 — intervention group
Group type: COMPARATOR
Intervention: Over-the-counter boil-and-bite mouthguard (BB)
Number of subjects: 42
Study 28538314 — intervention group
Group type: COMPARATOR
Intervention: No mouthguard (NO)
Number of subjects: 42
Study 25895948 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 38
Study 25895948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 24314842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 226
Study 24314842 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 226
Study 24314842 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 226
Study 22735869 — intervention group
Group type: EXPERIMENTAL
Intervention: Felypressin added to prilocaine
Number of subjects: 71
Study 22735869 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine without felypressin
Number of subjects: 71
Study 21203706 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite restorations (Excite/Tetric Ceram)
Number of subjects: 30
Study 21203706 — intervention group
Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RMGIC) (Vitremer/3M)
Number of subjects: 30
Study 18055943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 57
Study 18055943 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 57
Study 16350383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan-based heparin-bonded circuits
Number of subjects: 40
Study 12115160 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological interventions (e.g., relaxation, biofeedback, cognitive‐behavioral therapy)
Number of subjects: 25
Study 9857535 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (250 mg), Promethazine (300 mg), Dextran 70 (500 ml intraperitoneally)
Number of subjects: 30
Study 9857535 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 women)
Number of subjects: 30
Study 8589875 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided approach
Number of subjects: 345
Study 8589875 — intervention group
Group type: COMPARATOR
Intervention: Right-sided approach
Number of subjects: 345
Study 8589875 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided approach with submuscular or subcutaneous patch
Number of subjects: 345
Study 8589875 — intervention group
Group type: COMPARATOR
Intervention: Right-sided approach with submuscular or subcutaneous patch
Number of subjects: 345
Study 8589875 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided approach without submuscular or subcutaneous patch
Number of subjects: 345
Study 8589875 — intervention group
Group type: COMPARATOR
Intervention: Right-sided approach without submuscular or subcutaneous patch
Number of subjects: 345
Study 2112500 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 69
Study 2112500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 371803 — intervention group
Group type: EXPERIMENTAL
Intervention: Maytansine
Number of subjects: 54
Study 31302000 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration Therapy (AT) plus Lifestyle Therapy
Number of subjects: 171